Artesunate Dose Escalation for the Treatment of Uncomplicated Malaria in a Region of Reported Artemisinin Resistance: A Randomized Clinical Trial

BACKGROUND: The emergence of artemisinin resistance has raised concerns that the most potent antimalarial drug may be under threat. The currently recommended daily dose of artesunate (AS) is 4 mg/kg, and is administered for 3 days together with a partner antimalarial drug. This study investigated th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Bethell, Delia, Se, Youry, Lon, Chanthap, Tyner, Stuart, Saunders, David, Sriwichai, Sabaithip, Darapiseth, Sea, Teja-Isavadharm, Paktiya, Khemawoot, Phisit, Schaecher, Kurt, Ruttvisutinunt, Wiriya, Lin, Jessica, Kuntawungin, Worachet, Gosi, Panita, Timmermans, Ans, Smith, Bryan, Socheat, Duong, Fukuda, Mark M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2011
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3094355/
https://ncbi.nlm.nih.gov/pubmed/21603629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0019283
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia